Mesoblast: had US$103M of cash at June 30

Mesoblast Limited (ASX: MSB; Nasdaq: MESO) reported a cash balance of US$103 million as of June 30, 2026, according to its financial records. This figure reflects the company’s ongoing efforts to manage liquidity and extend its operational runway to support key development milestones across its pipeline of cell-based therapies.

The company has historically prioritized its Tier 1 product candidates, including programs targeting acute graft versus host disease, heart failure, and chronic low back pain. These initiatives are central to Mesoblast’s strategy to achieve regulatory milestones and drive long-term value.

In the first quarter of 2016 (ended September 30, 2015), Mesoblast reported cash reserves of $77.8 million, which were further augmented by $63.5 million in net proceeds from a public financing in November 2015. Over time, the company has implemented cost controls, reducing quarterly operating cash burn by approximately 20-25% compared to the prior two quarters.

The June 30, 2026, cash balance indicates continued financial stability, supporting the company’s ability to advance clinical trials and pursue strategic partnerships. Investors should note that Mesoblast’s cash flow and liquidity position are subject to ongoing operational and regulatory developments, as outlined in its SEC filings.